Editorial: Trajectory of soluble programmed cell death protein-1 and ligand-1 in HBV-infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Editorial: Trajectory of soluble programmed cell death protein-1 and ligand-1 in HBV-infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-07-17 , DOI: 10.1111/apt.18174
Chan Xie ₁

Affiliation

This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18142

中文翻译：

社论：用聚乙二醇化干扰素治疗的 HBV 感染者中可溶性程序性细胞死亡蛋白 1 和配体 1 的轨迹——对停止规则和 HBV 治疗计划的影响。作者回复

本文链接至 Chen 等人的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.18131 和 https://doi.org/10.1111/apt.18142

更新日期：2024-07-17

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>